Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MindWalk Holdings's share price for the quarter that ended in Jan. 2026 was $1.62. MindWalk Holdings's Shares Outstanding (EOP) for the quarter that ended in Jan. 2026 was 46.71 Mil. Therefore, MindWalk Holdings's market cap for the quarter that ended in Jan. 2026 was $75.67 Mil.
MindWalk Holdings's quarterly market cap
increased
from Jul. 2025 ($76.62 Mil) to Oct. 2025 ($86.31 Mil) but then
declined
from Oct. 2025 ($86.31 Mil) to Jan. 2026 ($75.67 Mil).
MindWalk Holdings's annual market cap
declined
from Apr. 2023 ($64.38 Mil) to Apr. 2024 ($34.49 Mil) and
declined
from Apr. 2024 ($34.49 Mil) to Apr. 2025 ($20.22 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MindWalk Holdings's Enterprise Value for Today is $69.18 Mil.
MindWalk Holdings (NAS:HYFT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
MindWalk Holdings Market Cap Related Terms
MindWalk Holdings Market Cap Historical Data
* Premium members only.
The historical data trend for MindWalk Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MindWalk Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindWalk Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindWalk Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where MindWalk Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
MindWalk Holdings's Market Cap for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindWalk Holdings (HYFT) has a Market Cap of $76.61 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MindWalk Holdings and its competitors. According to the industry distribution chart, MindWalk Holdings ranks #817 out of 1428 companies in the Biotechnology industry, placing it in the top 57.2%.
Is MindWalk Holdings' Market Cap too high?
MindWalk Holdings' current Market Cap is $76.61 Mil. The Biotechnology industry median Market Cap is 114.03. MindWalk Holdings' value of $76.61 Mil is 32.8% below this industry median. Based on the distribution chart, MindWalk Holdings ranks #817 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MindWalk Holdings has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' Market Cap compare to ANVS and GANX?
According to the Biotechnology industry distribution chart, MindWalk Holdings ranks #817 out of 1428 companies for Market Cap. This places MindWalk Holdings in the lower half of its industry. The industry median Market Cap is 114.03. MindWalk Holdings' value of $76.61 Mil is 32.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindWalk Holdings's current Market Cap of $76.61 Mil is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MindWalk Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindWalk Holdings's current Market Cap is $76.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.64 — trading 168.9% above its estimated fair value. The current Market Cap is $76.61 Mil and 32.8% below the Biotechnology industry median of 114.03. MindWalk Holdings' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current Market Cap is $76.61 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MindWalk Holdings (HYFT) Overvalued in 2026?
Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued.
The current stock price of $1.64 is trading 168.9% above its estimated GF Value™ of $0.61.
GuruFocus considers MindWalk Holdings to be Significantly Overvalued.
Key valuation signals for HYFT:
Market Cap: $76.61 Mil
GF Value™: $0.61 vs. price of $1.64 (168.9% above fair value)
Industry Position: 32.8% below the Biotechnology median (#817 of 1428)
No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
38GF Score
Get the complete analysis for HYFT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYFT has been successfully added to your 
